[{"id":"79d9e8dd-d27c-44f5-bb7c-a7b9337ae722","acronym":"HS-2020-07SZ","url":"https://clinicaltrials.gov/study/NCT04739826","created_at":"2022-04-24T09:03:01.372Z","updated_at":"2024-07-02T16:35:30.382Z","phase":"","brief_title":"Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04739826 - HS-2020-07SZ","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 491","initiation":"Initiation: 09/25/2020","start_date":" 09/25/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-03"},{"id":"4893e4f0-4406-4533-aee9-63908fb17f49","acronym":"FINESTdm","url":"https://clinicaltrials.gov/study/NCT04681820","created_at":"2021-01-19T20:46:48.858Z","updated_at":"2024-07-02T16:35:41.428Z","phase":"","brief_title":"Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib","source_id_and_acronym":"NCT04681820 - FINESTdm","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-08-01"},{"id":"d7a86641-98c9-4956-affb-39f8d249ddef","acronym":"","url":"https://clinicaltrials.gov/study/NCT05367765","created_at":"2022-05-10T20:53:41.698Z","updated_at":"2024-07-02T16:36:10.675Z","phase":"Phase 4","brief_title":"A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase","source_id_and_acronym":"NCT05367765","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Hansoh Xinfu (flumatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 2400","initiation":"Initiation: 04/30/2022","start_date":" 04/30/2022","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2022-05-10"},{"id":"a50d8b3f-f071-4492-bddf-6123f84c4988","acronym":"","url":"https://clinicaltrials.gov/study/NCT05353205","created_at":"2022-04-29T12:55:02.912Z","updated_at":"2024-07-02T16:36:11.215Z","phase":"Phase 4","brief_title":"A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.","source_id_and_acronym":"NCT05353205","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/23/2021","start_date":" 11/23/2021","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2022-04-29"},{"id":"49364708-2c78-4e7c-9120-a66a7b794b67","acronym":"","url":"https://clinicaltrials.gov/study/NCT04591197","created_at":"2021-01-18T21:53:45.613Z","updated_at":"2024-07-02T16:36:13.101Z","phase":"","brief_title":"Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04591197","lead_sponsor":"Nanfang Hospital of Southern Medical University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/09/2020","start_date":" 12/09/2020","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-04-12"},{"id":"09f9d97a-a744-4247-aed8-e90a950a29e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04677439","created_at":"2021-01-19T20:45:59.133Z","updated_at":"2024-07-02T16:36:15.296Z","phase":"Phase 4","brief_title":"Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure","source_id_and_acronym":"NCT04677439","lead_sponsor":"Shenzhen Second People's Hospital","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2022-03-16"},{"id":"cde53d08-8a5f-41ad-b3f9-dfdd4fa46826","acronym":"","url":"https://clinicaltrials.gov/study/NCT05071482","created_at":"2022-04-24T09:03:11.783Z","updated_at":"2024-07-02T16:36:23.299Z","phase":"Phase 4","brief_title":"Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL","source_id_and_acronym":"NCT05071482","lead_sponsor":"wang, jianxiang","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 238","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2021-10-08"}]